In this issue of JAMA Pediatrics, Pereira et al1 report on a sizable group of healthy newborns screened with whole-exome sequencing (WES) shortly after birth whose world—and the world of their parents—did not end in psychological and emotional Armageddon (so far). Does this mean that we are ready to offer WES to each of the 4 million infants born annually in the US? No. Does it mean that we have made a critical first step in understanding the potential benefits and harms of screening newborns with WES? Absolutely.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tarini BA. The Effect of BabySeq on Pediatric and Genomic Research—More Than Baby Steps. JAMA Pediatr. Published online August 23, 2021. doi:10.1001/jamapediatrics.2021.2826
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: